R. R. Bartlett

1.3k total citations
52 papers, 1.0k citations indexed

About

R. R. Bartlett is a scholar working on Immunology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, R. R. Bartlett has authored 52 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Immunology, 15 papers in Molecular Biology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in R. R. Bartlett's work include Immune Cell Function and Interaction (7 papers), T-cell and B-cell Immunology (7 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). R. R. Bartlett is often cited by papers focused on Immune Cell Function and Interaction (7 papers), T-cell and B-cell Immunology (7 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). R. R. Bartlett collaborates with scholars based in Germany, United States and United Kingdom. R. R. Bartlett's co-authors include H. U. Schorlemmer, R Schleyerbach, M Dimitrijevic, R. Kurrle, Iain Hagan, Mary Morphew, Alan Bridge, G. H. Thoenes, Claudius Küchle and Klaus Pfizenmaier and has published in prestigious journals such as The Journal of Experimental Medicine, Genes & Development and The Journal of Immunology.

In The Last Decade

R. R. Bartlett

47 papers receiving 928 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R. R. Bartlett Germany 19 435 255 156 107 103 52 1.0k
Michael Y. Fessing United States 22 1.0k 2.3× 136 0.5× 174 1.1× 358 3.3× 27 0.3× 32 2.3k
Ágota Szepesi Hungary 19 368 0.8× 244 1.0× 33 0.2× 317 3.0× 21 0.2× 49 997
Yukihiko Kato Japan 17 764 1.8× 161 0.6× 85 0.5× 232 2.2× 29 0.3× 55 1.2k
Kamel Izeradjene United States 13 724 1.7× 341 1.3× 86 0.6× 714 6.7× 20 0.2× 16 1.5k
Jennifer Cairns United Kingdom 17 336 0.8× 1.1k 4.4× 165 1.1× 155 1.4× 143 1.4× 29 1.7k
Hiroyoshi Wada Japan 13 640 1.5× 105 0.4× 47 0.3× 173 1.6× 16 0.2× 28 915
Ilan Bleiberg Israel 18 303 0.7× 115 0.5× 67 0.4× 149 1.4× 43 0.4× 46 718
Yutaka Enomoto Japan 22 692 1.6× 510 2.0× 30 0.2× 150 1.4× 18 0.2× 42 1.3k
Patrick B. Lappin United States 16 291 0.7× 137 0.5× 101 0.6× 174 1.6× 127 1.2× 26 674
Shoichiro Tsuji Japan 13 672 1.5× 418 1.6× 50 0.3× 726 6.8× 35 0.3× 20 1.4k

Countries citing papers authored by R. R. Bartlett

Since Specialization
Citations

This map shows the geographic impact of R. R. Bartlett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. R. Bartlett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. R. Bartlett more than expected).

Fields of papers citing papers by R. R. Bartlett

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. R. Bartlett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. R. Bartlett. The network helps show where R. R. Bartlett may publish in the future.

Co-authorship network of co-authors of R. R. Bartlett

This figure shows the co-authorship network connecting the top 25 collaborators of R. R. Bartlett. A scholar is included among the top collaborators of R. R. Bartlett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. R. Bartlett. R. R. Bartlett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schorlemmer, H. U., R. R. Bartlett, & R. Kurrle. (1999). Malononitrilamides prevent the generation of oxygen radicals in mononuclear phagocytes and graft rejection in a rat model. Transplantation Proceedings. 31(1-2). 851–853. 4 indexed citations
2.
Schorlemmer, H. U., R. Kurrle, R. Schleyerbach, & R. R. Bartlett. (1999). Generation of O 2 - radicals in macrophages can be inhibited in vitro and in vivo by derivatives of leflunomide's primary metabolite. Inflammation Research. 48(0). 117–118. 3 indexed citations
3.
Schorlemmer, H. U., et al.. (1999). Cell cycle regulation and inhibition of de novo pyrimidine biosynthesis by leflunomide. Inflammation Research. 48(0). 115–116. 3 indexed citations
4.
Dimitrijevic, M, et al.. (1999). Leflunomide protects mice from multiple low dose streptozotocin (MLD-SZ)-induced insulitis and diabetes. Clinical & Experimental Immunology. 117(1). 44–50. 17 indexed citations
5.
Schorlemmer, H. U., R. Kurrle, R. Schleyerbach, & R. R. Bartlett. (1999). Disease-modifying activity of malononitrilamides, derivatives of leflunomide's active metabolite, on models of rheumatoid arthritis. Inflammation Research. 48(0). 113–114. 7 indexed citations
6.
Schorlemmer, H. U., R. R. Bartlett, & R. Kurrle. (1998). Inhibition of Alloreactivity in the Popliteal Lymph Node Assay by Malononitrilamides. Transplantation Proceedings. 30(4). 968–970. 1 indexed citations
7.
Bridge, Alan, Mary Morphew, R. R. Bartlett, & Iain Hagan. (1998). The fission yeast SPB component Cut12 links bipolar spindle formation to mitotic control. Genes & Development. 12(7). 927–942. 118 indexed citations
8.
Schorlemmer, H. U., R. R. Bartlett, & R. Kurrle. (1997). Analogues of leflunomide's primary metabolite, the malononitrilamides, prevent the development of graft-versus-host disease. Transplantation Proceedings. 29(1-2). 1298–1301. 24 indexed citations
9.
Kurrle, R., E. Ruuth, R. R. Bartlett, L Lauffer, & H. U. Schorlemmer. (1997). Malononitrilamides inhibit T- and B-cell responsiveness in different species. Transplantation Proceedings. 29(1-2). 1302–1303. 30 indexed citations
10.
Kurrle, R., R. R. Bartlett, E. Ruuth, L Lauffer, & H. U. Schorlemmer. (1996). Malononitrilamides inhibit T- and B-cell responsiveness.. PubMed. 28(6). 3053–6. 14 indexed citations
11.
Hermann, Martin, et al.. (1995). The influence of leflunomide on cell cycle, IL-2-receptor (Il-2-R) and its gene expression. Inflammation Research. 44(3). 143–143. 3 indexed citations
12.
Mrowka, Christian, G. H. Thoenes, Karl Langer, & R. R. Bartlett. (1994). Prevention of the acute graft-versus-host disease (GVHD) in rats by the immunomodulating drug leflunomide. Annals of Hematology. 68(4). 195–199. 12 indexed citations
13.
Herrmann, Matthias, et al.. (1994). The influence of leflunomide on cell cycle, IL-2-receptor (IL-2-R) and its gene expression. Inflammation Research. 41(S2). C204–C205. 3 indexed citations
14.
Burkardt, Nina, Berton L. Lamb, & R. R. Bartlett. (1990). Self and organizational efficacy of front-line managers in the U.S. Fish and Wildlife Service. 12(3). 241–243. 1 indexed citations
15.
Bartlett, R. R., et al.. (1989). A ground-based air-operated launcher for parachute testing. 1 indexed citations
16.
17.
Thoenes, G. H., Thomas Sitter, Karl Langer, R. R. Bartlett, & R Schleyerbach. (1989). Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats. International Journal of Immunopharmacology. 11(8). 921–929. 32 indexed citations
18.
19.
Stockinger, Hannes, R. R. Bartlett, Klaus Pfizenmaier, Martin Röllinghoff, & Hermann Wagner. (1981). H-2 restriction as a consequence of intentional priming. Frequency analysis of alloantigen-restricted, trinitrophenyl-specific cytotoxic T lymphocyte precursors within thymocytes of normal mice.. The Journal of Experimental Medicine. 153(6). 1629–1639. 28 indexed citations
20.
Wagner, H., Conny Hardt, R. R. Bartlett, Martin Röllinghoff, & Klaus Pfizenmaier. (1980). Intrathymic differentiation of cytotoxic T lymphocyte (CTL) precursors. I. The CTL immunocompetence of peanut agglutinin-positive (cortical) and negative (medullary) Lyt 123 thymocytes.. The Journal of Immunology. 125(6). 2532–2538. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Y. Fessing Breakdown of academic impact, for papers by Ágota Szepesi Breakdown of academic impact, for papers by Yukihiko Kato Breakdown of academic impact, for papers by Kamel Izeradjene Breakdown of academic impact, for papers by Jennifer Cairns Breakdown of academic impact, for papers by Hiroyoshi Wada Breakdown of academic impact, for papers by Ilan Bleiberg Breakdown of academic impact, for papers by Yutaka Enomoto Breakdown of academic impact, for papers by Patrick B. Lappin Breakdown of academic impact, for papers by Shoichiro Tsuji
Rankless by CCL
2026